International Murex Gets What It Wants
Executive Summary
The $234 million purchase of International Murex Technologies Corp. by Abbott Laboratories may seem like a pricey deal, but it isn't if one considers that the whole of Murex is worth more than the sum of its parts. Murex has no stellar technology, but rather a broad portfolio of niche tests in virology and infectious diseases. Abbott is interested in Murex' blood banking business, its rapid HIV diagnostic assay, its attractive patent portfolio, and its microtiter plate technology.
You may also be interested in...
Innogenetics' New Chief Speaks Out
Philippe Archinard was one of the top executives at bioMerieux, the eighth largest diagnostics company, and a potential heir to Alain Merieux, the company's founder, when he left following disagreements with the new head of the company. He took a position as CEO of Innogenetics, a once high-flying biotech company with a strong emphasis on vaccines and molecular diagnostics. His mission: to fix the company's infrastructure so that it could grow, refocus its resources, and beef up its distribution in the wake of a disruption which occurred when its distribution and alliance partner International Murex was acquired by Abbott Labs in 1998.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.